Chromatin regulation
1Experimental research; clinical benefit is not established.
What does it do?
A KEDP bioregulator with prostate-related animal findings and limited human evidence.
Approved & studied uses
Evidence limits
View research →Human urinary or prostate benefits and treatment safety were not established.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Clinical gap
Lymphocyte chromatin experiments do not establish relief of prostate or urinary symptoms.1
Investigational; this profile does not establish an approved use.
Amino-acid sequence
- Lys
- Glu
- Asp
- Pro
4 residues · N → C1
Reference identity · not independently confirmed11
Length4 amino acids
Molecular weight · Da487.5 Da
Formula, sequence notation & identity
K–E–D–PLys–Glu–Asp–Pro (KEDP)
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pep-Pedia identity details
4 amino acids · 487.5 Da
Lys-Glu-Asp-Pro (KEDP)Reference description; checked chemical identity above takes precedence when available.11
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman kinetics not established1
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Scope of evidence
Human urinary or prostate benefits and treatment safety were not established.1
Reported timelines
Reference & communityReference expectations
Both routes: subtle 1–2 weeks, tissue/symptom claims 2–3, peak 3–4; animal extrapolation, not established human response.11
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Source & limitations
The source displays “74 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 0.5-1 mg daily | Once daily | Prostate Health SupportReference report | 10-20 days | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence. Source tabs Injectable | |||||
| SubQ | 0.75 mg daily | Once daily for 10-20 days | Anti-Aging ProtocolReference report | 10-20 days | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence. Source tabs Injectable | |||||
| OralOral capsule | 0.5-1 mg daily | Once daily on empty stomach | Prostate Health SupportReference report | 10-20 days | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence. Source tabs Oral | |||||
| Oral | 1 capsule daily | 30 minutes before meals | Standard ProtocolReference report | 10-20 days | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 10-20 days
- Break
- 4-6 month rest periods between cycles
Reported timing
Morning administration recommended
Oral
- Use period
- 10-20 days
- Break
- 4-6 month rest periods
Reported timing
Morning administration
Animal and cell protocols 1
Laboratory exposures cannot establish a human dose.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IM | 20 μg/kg | Daily for 15 days | Preclinical Reference (Rat Model)Reference report | 10-20 days | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence. Source tabs Injectable | |||||
No protocols match these filters.
Side effects & safety
Clinical gap
Lymphocyte chromatin experiments do not establish relief of prostate or urinary symptoms.
1Human exposure unknown
The reviewed experiment does not establish a therapeutic dose or an adverse-event rate in patients.
1Caution
Human safety uncertain; source flags active prostate malignancy.
Reported problems
Local irritation, GI symptoms and headache.
Stop symptoms
Urinary/prostate changes, infection, persistent headache/GI distress or allergy.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
5-alpha-reductase inhibitors
Caution reportedOverlapping prostate effects.11
Reference report · Pep-Pedia label: Use CautionTestosterone / TRT
Caution reportedProstate/PSA concerns.11
Reference report · Pep-Pedia label: Monitor CombinationEpitalon
Unverified pairingUnstudied pairing.11
Reference report · Pep-Pedia label: CompatibleThymalin
Unverified pairingUnstudied pairing.11
Reference report · Pep-Pedia label: CompatiblePinealon
Unverified pairingUnstudied pairing.11
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingUnstudied pairing.11
Reference report · Pep-Pedia label: CompatibleSaw palmetto
Unverified pairingCombination untested.11
Reference report · Pep-Pedia label: CompatibleOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.2
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source reports 2 mL for a 10 mg/mL preparation.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- That example implies 20 mg total vial content. · Reported storage: 2–8°C for 14 days.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
The source describes capsules taken 30 minutes before food.
- Form
- Source describes a prepared product
- Reported parameters
- Reported storage: cool, dry room-temperature conditions.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite Lyophilized PowderReported appearanceClear Reconstituted SolutionReported appearanceCertificate of AnalysisReported variationResearch Grade ProductReported concernDiscolored or Clumped PowderReported concernCloudy Solution
11Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
11Refrigerate at 2-8°C, use within 14 days
Room temperature, cool dry place
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalSource context
Short peptide length does not prove oral absorption or equivalence. Reference compatibility claims are not clinical safety evidence.
Compound identity & other names
Prostamax is the KEDP tetrapeptide. Verified original research measures cell responses; this is insufficient to establish a treatment for prostatitis, urinary symptoms or prostate enlargement.
Other names: KEDP
Investigational; this profile does not establish an approved use.
How it may work
Proposed prostate-cell regulation and chromatin effects; oral uptake is uncertain.11
Chromatin measurements in lymphocytes
The checked study examined chromatin thermal behavior in lymphocytes. It did not evaluate urinary symptoms or administer a validated prostate treatment to patients.
1Research areas and evidence gaps
Chromatin regulation. Experimental research; clinical benefit is not established.1
- Human urinary or prostate benefits and treatment safety were not established.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
The targeted newer-literature check did not identify an additional verified exact-compound clinical outcome study beyond the retained evidence. This is not a systematic-review conclusion.
- Checked
- 2026-10-12
- Search
- Prostamax 2025 2026 study; Prostamax peptide; 15612551
- Catalog
- Pep-Pedia ↗ · 9 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situAbstract checked
AI-PREPARED SUMMARY
Prostamax was examined through thermal/chromatin measurements in lymphocytes.
Chromatin measurements in lymphocytes
The checked study examined chromatin thermal behavior in lymphocytes. It did not evaluate urinary symptoms or administer a validated prostate treatment to patients.
Pep-Pedia bibliography · Checked 2026-10-12
2Pep-Pedia: ProstamaxCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
3Benign Prostatic Hyperplasia Model (2014)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A BPH animal model reportedly showed improved prostate weight and tissue appearance; human symptom or cancer outcomes were not assessed.
Reported population / model
Animal model
Reported study details
BPH parameters · Histological assessment
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Borovskaya, T.G., Pakhomova, A.V., Goldberg, V.E., et al. (2013). Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications. Modern Research in Inflammation, 2(3), 54-58.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat prostatitis models reportedly had less inflammation/scarring and more sexual activity; claims of superiority to comparators remain preclinical.
Reported population / model
Rat model
Reported study details
20 μg/kg IM daily · 45 days observation · Anti-inflammatory effects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Dzhokhadze, T.A., Buadze, T.Z., Gaĭozishvili, M.N., et al. (2012). Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro). Georgian Medical News, 212, 76-82.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Elderly-donor cell cultures showed relaxed chromatin packing; clinical prostate or aging outcomes were not studied.
Reported population / model
Human cell cultures
Reported study details
Elderly subjects · Chromatin relaxation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Khavinson, V.K., Lezhava, T.A., Malinin, V.V. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine, 137(1), 78-81.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Elderly-donor lymphocytes showed ribosomal-gene and chromatin changes, including specific chromosome regions.
Reported population / model
Human lymphocytes
Reported study details
Subjects aged 75-88 · Chromatin structure analysis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Khavinson, V.K. (2022). Peptide bioregulators: the new class of geroprotectors. Advances in Gerontology, 35(2), 156-164.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
8Borovskaya, T.G., Pakhomova, A.V., Goldberg, V.E., et al. (2013). Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications. Modern Research in Inflammation, 2(3), 54-58.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
9Khavinson, V.K., Lezhava, T.A., Malinin, V.V. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine, 137(1), 78-81.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Khavinson, V.K. (2022). Peptide bioregulators: the new class of geroprotectors. Advances in Gerontology, 35(2), 156-164.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Pep-Pedia: Prostamax — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12